HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DIOR SVELTE AD EFFECTIVENESS FIGURES WILL BE MODIFIED

This article was originally published in The Rose Sheet

Executive Summary

DIOR SVELTE AD EFFECTIVENESS FIGURES WILL BE MODIFIED to comply with a recommendation made by the National Advertising Division of the Council of Better Business Bureaus (NAD), NAD said in an Aug. 5 report on a review of claims in Christian Dior Perfumes' print ad for Dior Svelte Cellulite Control Complex. Based on its review, NAD concluded that "improvement percentages" used in the ad should "clearly disclose that they relate to the number of panel subjects and not a level of performance." Dior told NAD that it will "in future advertising follow...NAD's recommendation" even though the firm "believes that its advertising clearly communicates that the percentage of improvement contained therein refers to the subject participating in the clinical testing," the NAD case report stated.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel